Still SF [Two-Stage / GS Designs]

posted by ElMaestro  – Denmark, 2016-10-07 00:13 (3107 d 17:50 ago) – Posting: # 16702
Views: 14,157

Hello VStus,

❝ But back to reality: isn't it more practical in case of HVD to perform pilot on development with let's say 50% power (wondering: replicated pilot to keep reasonable small population?), better understand in-vitro in-vivo relationship, optimize formulation and than run replicate scaled trial? In 2-stage we also need to wait for results from the 1st stage...


Yes
Nitpicking: you perform a 2-stage trial or a pilot trial because you do not know the variability, right? Which means the "let's say 50% power" in actuality means guessworking. Optimizing the formulation on basis of a pilot trial with inherently low power (=high uncertainty on the PE) is in scientific terms as solid as tarot cards or crystal healing.
I read on LinkedIn the other day: "The flat earth society has members all over the globe" :-D:-D:-D

OK, surely I will get in trouble for this post.
:pirate:

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,422 posts in 4,927 threads, 1,668 registered users;
28 visitors (0 registered, 28 guests [including 11 identified bots]).
Forum time: 18:03 CEST (Europe/Vienna)

To know the history of science is to recognize the mortality
of any claim to universal truth.    Evelyn Fox Keller

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5